Decreased ADAMTS-13 (A disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure

被引:137
作者
Martin, Kenneth
Borgel, Delphine
Lerolle, Nicolas
Feys, Hendrik B.
Trinquart, Ludovic
Vanhoorelbeke, Karen
Deckmyn, Hans
Legendre, Paulette
Diehl, Jean-Luc
Baruch, Dominique [1 ]
机构
[1] INSERM, Unit 765, Paris, France
[2] Univ Paris 05, Paris, France
[3] Hop Europeen Georges Pompidou, AP HP, Serv Hematol Biol, Paris, France
[4] Hop Europeen Georges Pompidou, Serv Reanimat Med, Paris, France
[5] Hop Europeen Georges Pompidou, Epidemiol & Clin Res Unit, Paris, France
[6] Katholieke Univ Leuven, Lab Thrombosis Res, IRC, Kortrijk, Belgium
[7] INSERM, CIE4, Paris, France
[8] INSERM, Unit 770, F-94275 Le Kremlin Bicetre, France
[9] Univ Paris 11, Paris, France
关键词
severe sepsis; thrombosis; ADAMTS-13; von Willebrand factor;
D O I
10.1097/01.CCM.0000284508.05247.B3
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The inability to regulate the inflammatory response initiated upon infection leads to severe sepsis, characterized by widespread microvascular injury and thrombosis, organ ischemia, and dysfunction. A disintegrin-like and metalloprotease with thrombospondin type 1 repeats (ADAMTS)-13 regulates primary hemostasis by proteolyzing von Willebrand factor (VWF). Decreased ADAMTS-13 has been reported in disseminated intravascular coagulation due to severe sepsis. The present study investigates whether the sepsis-related dysregulation of endothelial activation leads to specific changes of ADAMTS-13. Design: Case-control study. Setting: Adult intensive care unit in a university hospital. Patients/Subjects. Three groups were studied: a case group of 30 patients with severe sepsis, a control group of 29 patients with comparable organ failure unrelated to sepsis, and 30 age- and gender-matched healthy subjects. Interventions: None. Measurements and Main Results: Significantly lower ADAMTS-1 3 activity was observed in patients with severe sepsis (43.2%; interquartile range, 32.7, 67.0) than in patients with organ failure unrelated to sepsis (67.8%; 57.4, 87.9; p < .05) and healthy subjects (105.6%; 87.2,125.6; p < .001). Accordingly, ADAMTS-13 antigen was more decreased in patients with severe sepsis than in patients with organ failure unrelated to sepsis and healthy subjects. VWF antigen was higher in patients with severe sepsis than in patients with organ failure unrelated to sepsis and healthy subjects. We found strong negative correlations in severe sepsis but not in organ failure unrelated to sepsis, between ADAMTS-13 activity and 1) VWF antigen; 2) thrombomodulin; 3) interleukin-6; 4) Acute Physiology and Chronic Health Evaluation 11 score; 5) shock; 6) acute renal injury. Moreover, patients above the median of ADAMTS-13 activity presented a higher survival compared with those below the median in the patients with severe sepsis but not in the patients with organ failure unrelated to sepsis. In contrast, there was no significant association between VWF antigen and survival in either the severe sepsis group or the group with organ failure unrelated to sepsis. Conclusions: We observed low ADAMTS-13 activity and antigen in severe sepsis and in other conditions associated with organ dysfunction. ADAMTS-13 levels were significantly associated with differences in morbidity, mortality, and variables of inflammation and endothelial dysregulation only in severe sepsis patients. This suggests that ADAMTS-13 deficiency may have a pathophysiological relevance specific to severe sepsis.
引用
收藏
页码:2375 / 2382
页数:8
相关论文
共 41 条
[1]   The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome [J].
Aird, WC .
BLOOD, 2003, 101 (10) :3765-3777
[2]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[3]   Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura [J].
Banno, F ;
Kokame, K ;
Okuda, T ;
Honda, S ;
Miyata, S ;
Kato, H ;
Tomiyama, Y ;
Miyata, T .
BLOOD, 2006, 107 (08) :3161-3166
[4]   Acute renal failure: time for consensus [J].
Bellomo, R ;
Kellum, J ;
Ronco, C .
INTENSIVE CARE MEDICINE, 2001, 27 (11) :1685-1688
[5]   Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[6]   Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow [J].
Bernardo, A ;
Ball, C ;
Nolasco, L ;
Moake, JF ;
Dong, JF .
BLOOD, 2004, 104 (01) :100-106
[7]   Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders:: a severely deficient activity is specific for thrombotic thrombocytopenic purpura [J].
Bianchi, V ;
Robles, R ;
Alberio, L ;
Furlan, M ;
Lämmle, B .
BLOOD, 2002, 100 (02) :710-713
[8]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[9]   Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis [J].
Borgel, D ;
Clauser, S ;
Bornstain, C ;
Bièche, I ;
Bissery, A ;
Remones, V ;
Fagon, JY ;
Aiach, M ;
Diehl, JL .
CRITICAL CARE MEDICINE, 2006, 34 (01) :219-222
[10]   Medical progress - Heat stroke [J].
Bouchama, A ;
Knochel, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (25) :1978-1988